$56.21 7.1%
CRSP Stock Price vs. AI Score (Last 150 days)
Data gathered: July 18

AI Score



Sign up to see AI score

Brand Score Sign up
Employment Score Sign up
User Growth Score Sign up
Fundamental Score Sign up

About Crispr Therapeutics

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for serious human diseases. The company develops its products using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), a gene editing technology that allows for precise directed changes to genomic DNA.


Crispr Therapeutics
Price $56.21
Target Price Sign up
Volume 1,950,000
Market Cap $5.26B
Year Range $51.17 - $89.12
Dividend Yield 0%
PE Ratio 13.4
Revenue per Employee $593,552
Industry Biotechnology

In the news


Financial performance View All

Revenue Cost of Revenue Gross Profit Net Income ebitda EPS
Q1 '24500,00018M-17M-117M-136M-1.430
Q4 '23201M16M185M89M74M1.100
Q3 '23018M-18M-112M-132M-1.410
Q2 '2370M19M51M-78M-90M-0.980
Q1 '23100M22M78M-53M-64M-0.670

Insider Transactions View All

Bruno Julianne filed to sell 6,745 shares at $56.1.
June 24 '24
Kulkarni Samarth filed to sell 208,122 shares at $60.4.
April 17 '24
Kulkarni Samarth filed to sell 209,326 shares at $59.9.
April 17 '24
Kulkarni Samarth filed to sell 208,122 shares at $73.1.
March 18 '24
Prasad Raju filed to sell 6,476 shares at $72.7.
March 18 '24

What is the Market Cap of Crispr Therapeutics?

The Market Cap of Crispr Therapeutics is $5.26B.

What is Crispr Therapeutics' PE Ratio?

As of today, Crispr Therapeutics' PE (Price to Earnings) ratio is 13.4.

How Many People Work at Crispr Therapeutics?

As of our latest update, Crispr Therapeutics employed approximately 458 people worldwide. However, it's important to note that Crispr Therapeutics' workforce size can fluctuate due to the company's growth, restructuring, or strategic shifts, so the current number of employees may be different.

What is Crispr Therapeutics' revenue per employee?

$593,552. To calculate Crispr Therapeutics' revenue per employee, we divide the company's total revenue in the last 4 quarters by its total number of employees.

What is the current stock price of Crispr Therapeutics?

Currently, the price of one share of Crispr Therapeutics stock is $56.21.

How can I analyze the CRSP stock price chart for investment decisions?

The CRSP stock price chart above provides a comprehensive visual representation of Crispr Therapeutics' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Crispr Therapeutics shares. Our platform offers an up-to-date CRSP stock price chart, along with technical data analysis and alternative data insights.

Does CRSP offer dividends to its shareholders?

As of our latest update, Crispr Therapeutics (CRSP) does not offer dividends to its shareholders. Investors interested in Crispr Therapeutics should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.

What are some of the similar stocks of Crispr Therapeutics?

Some of the similar stocks of Crispr Therapeutics are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.

.
The analytics provided are estimates and not a substitute for professional advice. All investments involve risks, including possible capital loss.
About Us

AltIndex revolutionizes investing with advanced alternative data analytics, smart insights, and stock alerts, presented in an easy-to-use dashboard powered by comprehensive company data from across the internet.



Legal Disclaimer
The information provided by AltIndex is solely for informational purposes and not a substitute for professional financial advice. Investing in financial markets carries inherent risks, and past performance doesn't guarantee future results. It's crucial to do your research, consult with financial experts, and align your financial objectives and risk tolerance before investing. AltIndex creators and operators are not liable for any financial losses incurred from using this information. Users should exercise caution, seek professional advice, and be prepared for the risks involved in trading and investing in financial assets, only investing what they can afford to lose. The information in this application, derived from publicly available data, is believed to be reliable but may not always be accurate or current. Users should verify information independently and not solely rely on this application for financial decisions. By using AltIndex, you acknowledge that it doesn't offer financial advice and agree to consult a qualified financial advisor before making investment decisions.

© 2024 AltIndex. All rights reserved.